Catheter Precision’s LockeT Sales Surge in Q2 2025

Catheter Precision ( (VTAK) ) has provided an update.

Catheter Precision announced that its LockeT product sales for Q2 2025 are on track to be the highest to date, surpassing Q2 2024 sales by over $84,000. The company has secured a new distributor in Italy and is seeking additional distributors in Spain, Portugal, and the UK, aiming to expand its European footprint. Three U.S. hospitals are expected to issue significant purchase orders for LockeT by the end of 2025, indicating strong market interest. The CE Mark approval for LockeT facilitates its sales in Europe, and a live demonstration is scheduled in Italy to boost product awareness.

Spark’s Take on VTAK Stock

According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.

The overall stock score reflects significant financial challenges faced by Catheter Precision, including declining revenues and negative cash flows. The technical analysis indicates potential short-term momentum but also highlights risks due to overbought conditions. The valuation is poor, with a negative P/E ratio and no dividend yield, reducing attractiveness. Corporate events further add to uncertainties.

To see Spark’s full report on VTAK stock, click here.

More about Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company focused on developing groundbreaking technology for electrophysiology procedures to improve the treatment of cardiac arrhythmias. The company collaborates with physicians to advance its products continuously.

Average Trading Volume: 13,328,381

Technical Sentiment Signal: Sell

Current Market Cap: $7.56M

See more insights into VTAK stock on TipRanks’ Stock Analysis page.